

TABLE I—ANALGESIC POTENCY OF PRODINE ENANTIOMERS

Compound	ED <sub>50</sub> <sup>a</sup> , mg./Kg.
<i>dl</i> - $\alpha$ -Prodine HCl	1.7
(+)- $\alpha$ -Prodine HCl	0.90
(-)- $\alpha$ -Prodine HCl	22.0
<i>dl</i> - $\beta$ -Prodine HCl	0.35
(+)- $\beta$ -Prodine HCl	0.25
(-)- $\beta$ -Prodine HCl	2.6
3-Desmethylprodine HCl	1.3
Meperidine HCl	12.0

<sup>a</sup> Analgesic activity was determined by a modified hot plate method (13).

method, it is very probable that Ib was only partially resolved.

It is significant that the C-3 asymmetric centers in the more potent isomers have opposite configurations. This, coupled with the observation that desmethylprodine (9) possesses greater potency than either of the less active prodine isomers (Table I) suggests that the 3-methyl group does not contribute to the drug-receptor interaction in a totally positive fashion. The difference in potency between (+)-Ia and (+)-Ib most probably is related to different brain levels<sup>1</sup> and it is conceivable that the lower potency of desmethylprodine, when compared to the more active antipodes, may largely be due to lower brain levels rather than to the absence of involvement of the 3-methyl group at the receptor level.

It is noteworthy that the more active enantiomers of isomethadone (VII) (10) and Ia are configurationally related (11). Since the desmethyl analog (VIII) (12) possesses potency which is comparable to VII, there exists the possibility that in this case the methyl group of (*S*)-isomethadone is also playing primarily a passive

<sup>1</sup> Preliminary experiments indicate that the brain levels of  $\beta$ -prodine in rats are greater than those of the  $\alpha$ -isomer and that this is the primary factor determining the potency difference between these diastereomers.

## 4,4'-Dihydroxybibenzyl, a Reduction Metabolite of *trans*-Stilbene

Sir:

Our investigations of the metabolism of certain stilbenes has revealed a unique conversion of *trans*-stilbene in rabbits (2.1%)<sup>1</sup> to 4,4'-dihydroxybibenzyl.

The above metabolite (originally designated X)

<sup>1</sup> Determined by VPC (TMS ether). Chromatographic analysis of urine obtained from guinea pigs administered *trans*-stilbene has indicated an even greater (10.6%) conversion to 4,4'-dihydroxybibenzyl.

role in the interaction with analgesic receptors.

- (1) Portoghesi, P. S., *J. Pharm. Sci.*, **55**, 865(1966).
- (2) Ziering, A., Motchane, A., and Lee, J., *J. Org. Chem.*, **22**, 1521(1957).
- (3) Archer, S., *Am. Chem. Soc., Abstr. Papers, 133rd Meeting*, San Francisco, April, 1958, p. 4M; Beckett, A. H., Casey, A. F., and Harper, H. J., *Chem. Ind. (London)*, **1959**, 485; Kartha, G., Ahmed, F. R., and Barnes, W. H., *Adv. Cryst.*, **13**, 525(1960); Ahmed, F. R., and Barnes, W. H., *ibid.*, **16**, 1249(1963).
- (4) Schultz, E. M., Robb, C. M., and Sprague, J. M., *J. Am. Chem. Soc.*, **69**, 2454(1947).
- (5) Sullivan, H. R., Beck, J. R., and Pohland, A., *J. Org. Chem.*, **28**, 2381(1963).
- (6) Casey, A. F., Beckett, A. H., Iorio, M. A., and Youssef, H. Z., *Tetrahedron*, **21**, 3387(1965).
- (7) Diamond, J., Bruce, W. F., and Tyson, F. T., *J. Med. Chem.*, **7**, 57(1964).
- (8) Randell, L. O., and Lehmann, G. L., *J. Pharmacol. Exptl. Therap.*, **93**, 314(1948).
- (9) Ziering, A., Berger, L., Heineman, S. D., and Lee, J., *J. Org. Chem.*, **12**, 894(1947).
- (10) Leimbach, D. G., and Eddy, N. B., *J. Pharmacol. Exptl. Therap.*, **110**, 135(1954).
- (11) Beckett, A. H., Kirk, G., and Thomas, R., *J. Chem. Soc.*, **1962**, 1386.
- (12) Branden, O. J., Eddy, N. B., and Halbach, H., *Bull. World Health Org.*, **13**, 937(1955).
- (13) Marshall, F. N., Jones, W. R., and Weaver, L. C., *Proc. Soc. Exptl. Biol. Med.*, **116**, 912(1964).

PHILIP S. PORTOGHESE

DENNIS L. LARSON

Department of Medicinal Chemistry  
College of Pharmacy  
University of Minnesota  
Minneapolis, MN 55455

Received November 15, 1967

Accepted for publication February 9, 1968.

This investigation was supported by research grant NB 05192 from the National Institutes of Health.

The authors gratefully acknowledge the generosity of Dr. W. E. Scott, Hoffmann-LaRoche, Inc., for providing a supply of  $\alpha$ - and  $\beta$ -prodine alcohol, and Dr. A. Pohland, Lilly Research Laboratories, for the specimen of (-)- $\beta$ -dimethylamino- $\alpha$ -methylpropionophenone hydrochloride. We also are indebted to Dr. H. Kupferberg of the University of Minnesota for his aid in the pharmacological testing.



### Keyphrases

Prodine enantiomers—absolute stereochemistry

Optical rotation—structure

IR spectrophotometry—structure

NMR spectroscopy—structure

ED<sub>50</sub>—prodine enantiomers

Absolute configuration—analgesic activity

was found in a phenolic fraction obtained from an ether extract of urine of rabbits, which had been administered *trans*-stilbene (25 mg./Kg., i.m.). Paper, thin-layer, and vapor phase chromatography (VPC) (1) of this phenolic fraction disclosed the presence of the *trans*-stilbenes, 4-hydroxy-, 4,4'-dihydroxy-, 3-hydroxy-4-methoxy-, and 4-hydroxy-3-methoxystilbene, and X, which was not comparable to these or other simple phenolic stilbenes. A 2-mg. sample of the trimethylsilyl (TMS) ether of X, obtained by preparative VPC, was subjected to IR, UV, and mass spectral analysis.

The IR spectrum of the TMS derivative of X,

except for differences in the fingerprint region, was similar to that of reference 4-trimethylsiloxy- and 4,4'-di(trimethylsiloxy)stilbene. The UV spectrum, however, with a single  $\lambda_{\max}$  at 280  $m\mu$ , was atypical for the *trans*-stilbene chromophore (2). Mass spectral analysis<sup>2</sup> of the isolated derivative showed a weak parent peak at  $m/e = 358$ , a base peak at  $m/e = 179$ , and other prominent peaks at  $m/e = 286$  and  $m/e = 107$ .


With these data, structure I was proposed for the TMS derivative of X and its mass spectral breakdown was rationalized as in Scheme I.

Based upon this determined molecular weight of 358, a molar absorptivity of 3460 (at 280  $m\mu$ ) was calculated for the TMS derivative of X and this provided additional evidence for the proposed structure (3).

The TMS derivative of X was found to co-chromatograph (VPC) with the di-TMS ether of authentic 4,4'-dihydroxybibenzyl. Hydrolysis of the isolated TMS derivative of X and comparison of the product (X) with 4,4'-dihydroxybibenzyl showed complete agreement in mobility and reaction to diazotized sulfanilic acid in three thin-layer systems and further substantiated the identity of X as 4,4'-dihydroxybibenzyl.

The formation of a bibenzyl derivative, a reduction product from *trans*-stilbene, involves a novel metabolic transformation for this class of compounds. In contrast, metabolic schemes incorporating reductions are well established for nitro- and azo-compounds, including the reduction of the stilbene isostere, azobenzene to hydrazobenzene (4), a postulated intermediate in the reductive cleavage of azobenzene (5). Reports of metabolic reductions of carbon-carbon double bonds are primarily limited to  $\Delta^4$ -3-keto-steroids (6, 7) and certain cinnamic acid derivatives (8). These reductions are analogous to the well-known hydrogenations of  $\alpha,\beta$ -unsaturated carbonyl compounds which occur in intermediary metabolism. Reductions resembling the one found in the present investigation, however, are rare and in combination with the implied reductive step in the formation of 1,2-dihydronaphthols (9), advance the significance of hydrogenation in the metabolism of similar conjugated ethylenic compounds.

<sup>2</sup> The authors are indebted to Luther H. Smithson, Jr., and Rick Faubert of Varian Associates, Palo Alto, Calif., for the mass spectral data.



- (1) Sinsheimer, J. E., and Smith, R. V., *J. Pharm. Sci.*, **56**, 1280 (1967).
- (2) Roe, E. M. F., *Spectrochim. Acta*, **11**, 515(1957).
- (3) Hunter, R. F., Morton, R. A., and Carpenter, A. T., *J. Chem. Soc.*, **1950**, 441.
- (4) Bray, H. G., Clowes, R. C., and Thorpe, W. V., *Biochem. J.*, **49**, 65(1951).
- (5) Fouts, J. R., Kamm, J. J., and Brodie, B. B., *J. Pharmacol. Exptl. Therap.*, **120**, 291(1957).
- (6) Okado, H., Matsuyoshi, K., and Tokuda, G., *Acta Endocrinol. (Copenhagen)*, **46**, 40(1964).
- (7) Yates, E. F., Herbst, A. L., and Urquhart, J., *Endocrinology*, **63**, 887(1958).
- (8) Booth, A. N., Emerson, O. H., Jones, F. T., and DeEds, F., *J. Biol. Chem.*, **229**, 51(1957).
- (9) Boyland, E., and Solomon, J. B., *Biochem. J.*, **59**, 522 (1955).

JOSEPH E. SINSHEIMER  
ROBERT VICTOR SMITH\*

College of Pharmacy  
University of Michigan  
Ann Arbor, MI 48104

Received December 5, 1967.

Accepted for publication January 10, 1968.

This investigation was supported in part by Public Health Service training grant GM 1367.

\* Present address: College of Pharmacy, The University of Iowa, Iowa City, IA 52240

### Keyphrases

*trans*-Stilbene—conversion in rabbits  
4,4'-Dihydroxybibenzyl—urinary metabolite *trans*-stilbene  
Vapor phase chromatography—identity  
TLC—identity  
IR spectrophotometry—identity  
UV spectrophotometry—identity  
Mass spectroscopy—structure